Sanofi (NASDAQ: SNY) reported Q4 EPS of EUR1.53, EUR0.69 better than the analyst estimate of EUR0.84. Revenue for the quarter came in at EUR11.3 billion versus the consensus estimate of EUR13.58 billion.

Guidance

In 2026, sales are expected to grow by a high single-digit percentage at CER. Business EPS at CER is expected to grow slightly faster than sales (before share buyback), delivering profitable growth.4 Sanofi intends to execute a share buyback program in 2026 of €1 billion.

For earnings history and earnings-related data on Sanofi (SNY) click here.